MedWatch

Topotarget-medicine gets Orphan Drug-status

The European Medicines Agency (EMA) has approved a candidate drug from Topotarget as an Orphan Drug. The decision provides the Danish biotech company with far better conditions for developing the drug.

Topotarget’s candidate drug belinostat has achieved Orphan Drug-status in the EU for the treatment of the indication Peripheral T-Cell Lymphoma (PTCL).

“Gaining Orphan Drug-status for belinostat for the treatment of PTCL in the European Union is an important milestone in our efforts to submit a registration application in this region. This is great news for Topotarget and potentially to patients with the rare disease PTCL, who are in need of new treatment options,” says CEO Anders Fink Vadsholt in a stock market release.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier